3,435.00
+130(+3.93%)
Currency In KRW
Sector
Healthcare
Industry
Biotechnology
Employees
43
First IPO Date
December 06, 2016
| Name | Title | Pay | Year Born |
| Mr. Jaekyung Kim | Chief Executive Officer & Chairman of the Board | 0 | 1964 |
| Mr. Eun-Ki Min | Chief Accounting Officer and Executive Director | 0 | N/A |
| Mr. Jaejeong Lee | Executive Officer | 0 | 1971 |
| Mr. TaeGyun Kim | President | 0 | 1963 |
| Mr. SangGeun Park | Executive Director | 0 | 1976 |
| Chan Kwon Hyuk M.D., Ph.D. | Chief Medical Officer | 0 | N/A |
| Suk Song Myung | Chief Financial Officer | 0 | N/A |
| Mr. Jeongseok Lee | Executive Officer | 0 | 1982 |
| Mee Yang Kyung Ph.D. | Head of R&D Strategic Planning | 0 | N/A |
| Mr. SeungHwan Cho | Executive Officer | 0 | 1978 |
SillaJen, Inc. engages in the development and commercialization of oncolytic immunotherapy products. The company's lead product is Pexa-Vec, which is in Phase II clinical trial for the treatment of advanced liver cancer. It also develops JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. The company was founded in 2006 and is headquartered in Seoul, South Korea.